NCT04926194View on ClinicalTrials.gov

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

June 9, 2021

Study Completion Date

June 9, 2021

Conditions
Myelodysplastic/Myeloproliferative NeoplasmSteroid Refractory GVHDAllogeneic Hematopoietic Cell Transplant
Interventions
BIOLOGICAL

Decidual stromal cells (DSC)

DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT04926194 - Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Biotech Hunter | Biotech Hunter